Research programme: antifibrotic monoclonal antibodies - Sorrento Therapeutics

Drug Profile

Research programme: antifibrotic monoclonal antibodies - Sorrento Therapeutics

Alternative Names: WISP1 immunotherapy

Latest Information Update: 28 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Comprehensive Pneumology Center; Sorrento Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action WISP1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Idiopathic pulmonary fibrosis

Most Recent Events

  • 26 Aug 2014 Sorrento Therapeutics receives SBIR grant from US National Institutes of Health for Monoclonal antibody development in Idiopathic pulmonary fibrosis
  • 26 Aug 2014 Early research in Idiopathic pulmonary fibrosis in USA and Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top